Gibson Dunn Advises Neurogene Inc. on Establishing At-the-Market Facility for Sale of up to $150 Million of Common Stock

Firm News  |  August 13, 2025

---

Gibson Dunn represented Neurogene Inc. on establishing an at-the-market facility for the sale of up to $150 million of its common stock.

Neurogene Inc. is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders.

Gibson Dunn regularly advises life sciences companies on capital markets transactions, including at-the-market offerings and equity financings.

The Gibson Dunn team included Branden Berns, Ryan Murr, Candice Johnson, and Anika Gidwani.